# US 2025/0367121 A1 · Dosage forms comprising active pharmaceutical ingredients

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0367121 A1
- Document ID: US20250367121A1
- Status: Published application
- Kind: A1
- Application number: 19/266,899
- Filed: 2025-07-11
- Published: 2025-12-04
- Earliest claimed: 2018-09-28
- Assignees: Axsome Therapeutics, Inc.
- Applicants: Axsome Therapeutics, Inc.
- Inventors: Herriot Tabuteau
- Web page: https://patentgrep.com/patent/US20250367121A1

## CPC

- A61K 9/205: {Polysaccharides, e.g. alginate, gums; Cyclodextrin}
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 9/2009: {Inorganic compounds}
- A61K 9/2086: {Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat (active cores with a complete drug-free outer coat A61K9/28)}
- A61K 9/209: {containing drug in at least two layers or in the core and in at least one outer layer}
- A61K 31/192: having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid {(cannabinoids A61K31/658)}
- A61K 31/4045: Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
- A61K 31/4184: condensed with carbocyclic rings, e.g. benzimidazoles
- A61K 31/4196: 1,2,4-Triazoles
- A61K 31/5415: ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
- A61K 47/6951: {using cyclodextrin (cyclodextrins used as simple excipients A61K47/40)}
- C08B 37/0015: {Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C08B: POLYSACCHARIDES; DERIVATIVES THEREOF (polysaccharides containing less than six saccharide radicals attached to each other by glycosidic linkages C07H; fermentation or enzyme-using processes C12P19/00; sugar industry C13; production of cellulose D21)

## Abstract

Disclosed herein are dosage forms comprising a combination of: 1) an active pharmaceutical ingredient (API), 2) a cyclodextrin, and 3) a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the drug for the treatment of conditions such as pain.

## Claims

### Claim 1

A solid dosage form comprising a combination of: 1) naproxen or a pharmaceutically acceptable salt thereof, 2) sumatriptan or a pharmaceutically acceptable salt thereof, 3) a cyclodextrin, and 4) a bicarbonate.

### Claim 2 (depends on 1)

The solid dosage form of claim 1, comprising about 0.001 mg to about 1000 mg of the naproxen or the pharmaceutically acceptable salt thereof.

### Claim 3 (depends on 2)

The solid dosage form of claim 2, comprising about 20 mg to about 600 mg of the naproxen or the pharmaceutically acceptable salt thereof.

### Claim 4 (depends on 3)

The solid dosage form of claim 3, comprising about 500 mg of the naproxen or the pharmaceutically acceptable salt thereof.

### Claim 5 (depends on 3)

The solid dosage form of claim 3, comprising about 60 mg of the naproxen or the pharmaceutically acceptable salt thereof.

### Claim 6 (depends on 1)

The solid dosage form of claim 1, comprising about 0.001 mg to about 1000 mg of the sumatriptan or the pharmaceutically acceptable salt thereof.

### Claim 7 (depends on 6)

The solid dosage form of claim 6, comprising about 1 mg to about 200 mg of the sumatriptan or the pharmaceutically acceptable salt thereof.

### Claim 8 (depends on 7)

The solid dosage form of claim 7, comprising about 85 mg of the sumatriptan or the pharmaceutically acceptable salt thereof.

### Claim 9 (depends on 7)

The solid dosage form of claim 7, comprising about 10 mg of the sumatriptan or the pharmaceutically acceptable salt thereof.

### Claim 10 (depends on 1)

The solid dosage form of claim 1, comprising naproxen sodium.

### Claim 11 (depends on 1)

The solid dosage form of claim 1, comprising sumatriptan succinate.

### Claim 12 (depends on 1)

The solid dosage form of claim 1, comprising 1) about 500 mg of naproxen sodium and 2) about 85 mg of sumatriptan succinate.

### Claim 13 (depends on 1)

The solid dosage form of claim 1, comprising 1) about 60 mg of naproxen sodium and 2) about 10 mg of sumatriptan succinate.

### Claim 14 (depends on 1)

The solid dosage form of claim 1, wherein the cyclodextrin is a sulfobutylether β-cyclodextrin (SBEβCD).

### Claim 15 (depends on 14)

The solid dosage form of claim 14, wherein the SBEβCD has about 6 to about 7 sulfobutyl ether groups for each molecule of β-cyclodextrin.

### Claim 16 (depends on 15)

The solid dosage form of claim 15, comprising about 100 mg to about 500 mg of the SBEβCD.

### Claim 17 (depends on 16)

The solid dosage form of claim 16, comprising about 100 mg to about 175 mg of the SBEβCD.

### Claim 18 (depends on 16)

The solid dosage form of claim 16, comprising about 100 mg to about 140 mg of the SBEβCD.

### Claim 19 (depends on 1)

The solid dosage form of claim 1, wherein the bicarbonate comprises sodium bicarbonate.

### Claim 20 (depends on 1)

The solid dosage form of claim 1, comprising about 400 mg to about 1000 mg of the bicarbonate.

### Claim 21 (depends on 19)

The solid dosage form of claim 19, comprising about 500 mg of sodium bicarbonate.

### Claim 22 (depends on 1)

The solid dosage form of claim 1, which is used for the treatment of pain, inflammation, or a related condition, or a combination thereof.
